Document is current
Any future updates will be listed below
-
Authors
Guldan, Mustafa https://orcid.org/0000-0002-0480-5370
Ozbek, Lasin https://orcid.org/0000-0002-2828-555X
Fidan, Derya G. https://orcid.org/0009-0000-6686-9604
Narin, Arif E.
Hansen, Ditte https://orcid.org/0000-0003-4929-7901
Diaz-Tocados, Juan M. https://orcid.org/0000-0001-5192-5212
Haarhaus, Mathias https://orcid.org/0000-0001-8274-6356
de Borst, Martin H. https://orcid.org/0000-0002-4127-8733
Alfieri, Carlo https://orcid.org/0000-0003-3860-5219
Ferraro, Pietro M.
Bellasi, Antonio https://orcid.org/0000-0001-7830-1645
Kanbay, Mehmet https://orcid.org/0000-0002-1297-0675
-
Funding
Funding for this research was provided by:
Koc University
- License Information
-
More Information
Article History
Received: 2 February 2026
Accepted: 17 April 2026
First Online: 30 April 2026
Declarations
:
: PMF received consultant fees and grant/other support from Allena Pharmaceuticals, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer, Gilead, EG Stada, Novartis, Novo Nordisk, Otsuka Pharmaceuticals, Rocchetta, Vifor Fresenius, and royalties as an author for UpToDate. MHB received consultancy fees and grant/other support from Astellas, Astra Zeneca, Bayer, Boehringer, Ingelheim, CSL Vifor, Kyowa Kirin Pharma, Lilly, Sanofi Genzyme, all to institution. MH is an employee of Diaverum and advisory board member of Resverlogix. Other authors declare that there are no conflicts of interest.
: Not applicable.
: Not applicable.
